Articles tagged with: 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)

New South Wales puts 9000 people on PrEP, achieves a one-third decline in new HIV infections

published: March, 20, 2018 Written by // Guest Authors - Revolving Door Categories // Activism, Social Media, As Prevention , Gay Men, Current Affairs, Treatment Guidelines -including when to start, Health, International , Revolving Door, Treatment, Media, Guest Authors

Successful appeal to state government got ‘cap’ lifted on PrEP demo trial. From AIDSmap, Gus Cairns reports.

New South Wales puts 9000 people on PrEP, achieves a one-third decline in new HIV infections

The state of New South Wales in Australia has seen a fall of one-third in diagnoses of recent HIV infection since it started its pre-exposure prophylaxis (PrEP) implementation project, EPIC-NSW (Expanded PrEP Implementation in the Community), the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) heard last week. Andrew Grulich of the Kirby Institute of the University of New South Wales told the conference that only two people who entered EPIC-NSW had been diagnosed wi

How much "PrEP-resistant" HIV is out there?

published: March, 12, 2018 Written by // Guest Authors - Revolving Door Categories // International AIDS Conference , Social Media, As Prevention , Gay Men, Conferences, Current Affairs, Treatment Guidelines -including when to start, Health, Research, International , Revolving Door, Treatment, Media, Guest Authors

From AIDSmap, Gus Cairns reports from the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018).

How much

A study presented at the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) aims to quantify how many people with HIV there might be in the community who both have a detectable HIV viral load and also have significant resistance to tenofovir and emtricitabine, the two drugs currently used in pre-exposure prophylaxis (PrEP). The researchers, from the University of Washington in Seattle, found that in King County, which contains Seattle, no more than 0.3% of the l

New HIV infections halved after scale-up of HIV treatment, circumcision, in Uganda's hardest-hit district

published: March, 08, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, African, Caribbean and Black, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Health, International , Revolving Door, Treatment, Media, Guest Authors

From AIDSmap, Michael Carter and Keith Alcorn report on the Rakai Community Cohort Study.

New HIV infections halved after scale-up of HIV treatment, circumcision, in Uganda's hardest-hit district

The rate of new HIV infections has halved since 2011 in a Ugandan community following large increases in male circumcision, antiretroviral treatment and viral suppression, Frank Kagaayi of the Rakai Health Sciences Program told the Conference on Retroviruses and Opportunistic Infections in Boston on Tuesday. Dr Kagaayi was presenting results from the Rakai Community Cohort Study, focusing on repeat surveys of one fishing village with a very high prevalence and incidence of HIV infection. The

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys

published: March, 07, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, International AIDS Conference , As Prevention , Conferences, Current Affairs, Treatment Guidelines -including when to start, Research, Health, International , Revolving Door, Treatment, Media, Guest Authors

Five of eleven treated animals still remained virally suppressed at six months. From AIDSmap, Liz Highleyman reports.

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys

Dan Barouch presenting at CROI 2018. Photo by Liz Highleyman Treatment with a broadly neutralising antibody plus an immune-stimulating drug led to long-term viral remission after interrupting antiretroviral therapy in a monkey study, according to data presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) this week in Boston. Monkeys that received both the antibody, known as PGT121, and the TLR7 agonist GS-9620 maintained an undetectable viral load withou